EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

App-based self-administered biofeedback for the prevention of episodic migraine: A randomized controlled trial

Amalie Christine Poole iD, Anker Stubberud iD, Melanie Rae Simpson, Lise Rystad Øie iD, Erling Tronvik iD, Espen Saxhaug Kristoffersen iD, Marte-Helene Bjørk iD, Iben Cornelia Keim Larsen, Kjersti Grøtta Vetvik iD, Nina Bäcklund, Joakim Høgsteggen Østhus iD, Joan Crespi und 7 weitere

Cephalalgia · 2026

DOI: 10.1177/03331024261480724 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, 2026. Verfasst von Amalie Christine Poole und 18 weiteren Autor:innen. Beteiligte Einrichtung: Norwegian Centre for Headache Research, Norwegian University of Science and Technology, Trondheim, Norway. Hauptthemen laut MEDLINE: Migraine Disorders, Biofeedback, Psychology, Mobile Applications. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Oslo Regional Research Fund, Eurostars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To evaluate the efficacy and safety of a fully self-administered, app-based biofeedback intervention for the prevention of episodic migraine Methods This open-label, randomized, waitlist-controlled multicenter trial included adults with episodic migraine assigned to 12 weeks of daily biofeedback or a waitlist control. The primary outcome was change in monthly migraine days (MMDs) from baseline to weeks 9–12. Secondary outcomes included migraine intensity, acute medication use, and migraine-specific quality of life (MSQ v2.1). Statistical analyses were performed according to the intention-to-treat principle by a statistician masked to treatment assignment.

Results

Of 1113 individuals screened, 279 participants (mean [SD] age, 41 [10] years; 92% women) were randomized to the intervention (n = 140) or waitlist control (n = 139). Baseline MMDs were 4.8 (2.4) and 4.6 (2.3) in the intervention and control groups, respectively. During weeks 9–12, the estimated reduction in MMDs was 0.9 days (95% CI, −1.4 to −0.5) in the intervention group and 0.0 days (95% CI, −0.5 to 0.4) in the control group (between-group difference, 0.9 days; 95% CI, 0.3 to 1.5; P = 0.002). Participants receiving biofeedback also showed greater improvements in MSQ v2.1 total scores (mean difference, 5.3 points; 95% CI, 2.1 to 8.6; P = 0.001). Nine device-related adverse events occurred, all with mild severity.

Conclusion

App-based self-administered biofeedback was associated with a statistically significant reduction in migraine frequency and improved quality of life, with a favorable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersBiofeedback, PsychologyMobile ApplicationsHumansFemaleAdultMaleTreatment OutcomeMiddle AgedQuality of Life

Stichwörter der Autor:innen

behavioral treatmentbiofeedbackdigital therapeuticsepisodic migrainemHealthmigraine

Autor:innen und Institutionen

  • Norwegian Centre for Headache Research, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Neuromedicine and Movement Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Neurology and Neurophysiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
  • Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of General Practice, University of Oslo, Oslo, Norway.
  • Department of Neurology, Akershus University Hospital, Lørenskog, Norway.

ORCID-Profile: Amalie Christine Poole, Anker Stubberud, Lise Rystad Øie, Erling Tronvik, Espen Saxhaug Kristoffersen, Marte-Helene Bjørk, Kjersti Grøtta Vetvik, Joakim Høgsteggen Østhus, Oda Vardenær Lunder, Alexander Olsen, Mattias Linde, Tore Wergeland

Förderung

  • Oslo Regional Research Fund
  • Eurostars

Zitieren

APA

Poole, A. C., Stubberud, A., Simpson, M. R., Øie, L. R., Tronvik, E., Kristoffersen, E. S., Bjørk, M. H., Larsen, I. C. K., Vetvik, K. G., Bäcklund, N., Østhus, J. H., Crespi, J., Lunder, O. V., Khanevski, A. N., Øvrevik, A. B., Olsen, A., Linde, M., Salvesen, Ø., & Wergeland, T. (2026). App-based self-administered biofeedback for the prevention of episodic migraine: A randomized controlled trial. Cephalalgia. https://doi.org/10.1177/03331024261480724

Vancouver

Poole AC, Stubberud A, Simpson MR, Øie LR, Tronvik E, Kristoffersen ES, et al. App-based self-administered biofeedback for the prevention of episodic migraine: A randomized controlled trial. Cephalalgia. 2026. doi:10.1177/03331024261480724

BibTeX
@article{Poole2026,
  author = {Poole, Amalie Christine and Stubberud, Anker and Simpson, Melanie Rae and Øie, Lise Rystad and Tronvik, Erling and Kristoffersen, Espen Saxhaug and Bjørk, Marte-Helene and Larsen, Iben Cornelia Keim and Vetvik, Kjersti Grøtta and Bäcklund, Nina and Østhus, Joakim Høgsteggen and Crespi, Joan and Lunder, Oda Vardenær and Khanevski, Andrej Netland and Øvrevik, Ane Bakke and Olsen, Alexander and Linde, Mattias and Salvesen, Øyvind and Wergeland, Tore},
  title = {App-based self-administered biofeedback for the prevention of episodic migraine: A randomized controlled trial},
  journal = {Cephalalgia},
  year = {2026},
  doi = {10.1177/03331024261480724}
}
Kostenlos starten →